Β-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: A randomized pilot study

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Hanson, Kimberly E ^a   Pfeiffer, Christopher D ^b   Lease, Erika D ^c   Balch, Alfred H ^a   Zaas, Aimee K ^c   Perfect, John R ^c   Alexander, Barbara D ^c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN;

ADULT; ARTICLE; CANDIDIASIS; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPOCALCEMIA; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MYCOSIS; PHYSICIAN; PILOT STUDY; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; BETA-GLUCANS; CANDIDIASIS, INVASIVE; DEMOGRAPHY; ECHINOCANDINS; FALSE POSITIVE REACTIONS; FEASIBILITY STUDIES; FEMALE; HUMANS; INTENSIVE CARE UNITS; KINETICS; MALE; MIDDLE AGED; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; TIME FACTORS; YOUNG ADULT;

EID: 84864702571     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042282     Document Type: Article

References (41)

1. Falagas ME, Apostolou KE, Pappas VD, ((2006)) Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis 25:419-425.
2. Fridkin SK, ((2005)) Candidemia is costly-plain and simple. Clin Infect Dis 41:1240-1241.
3. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, et al. ((2005)) The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 41:1232-1239.
4. Pfaller MA, Jones RN, Doern GV, Sader HS, Hollis RJ, et al. ((1998)) International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group. J Clin Microbiol 36:1886-1889.
5. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, et al. ((2004)) Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39:309-317.
6. Pfaller MA, Jones RN, Doern GV, Sader HS, Messer SA, et al. ((2000)) Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob Agents Chemother 44:747-751.
7. Playford EG, Webster AC, Sorrell TC, Craig JC, ((2006)) Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. Journal of Antimicrobial Chemotherapy 57:628-638.
8. Schuster MG, Edwards JE Jr, Sobel JD, Darouiche RO, Karchmer AW, et al. ((2008)) Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med 149:83-90.
9. Parkins MD, Sabuda DM, Elsayed S, Laupland KB, ((2007)) Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. Journal of Antimicrobial Chemotherapy 60:613-618.
10. Ostrosky-Zeichner L, Pappas PG, Shoham S, Reboli A, Barron MA, et al. ((2011)) Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. Mycoses 54:46-51.
11. Ostrosky-Zeichner L, Sable C, Sobel J, Alexander B, Donowitz G, et al. ((2007)) Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. European Journal of Clinical Microbiology & Infectious Diseases 26:271-276.
12. Leon C, Ruiz-Santana S, Saavedra P, Almirante B, Nolla-Salas J, et al. ((2006)) A bedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 34:730-737.
13. Leon C, Ruiz-Santana S, Saavedra P, Galvan B, Blanco A, et al. ((2009)) Usefulness of the "Candida score" for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med 37:1624-1633.
14. Alexander BD, Smith PB, Davis RD, Perfect JR, Reller LB, ((2010)) The (1,3){beta}-D-glucan test as an aid to early diagnosis of invasive fungal infections following lung transplantation. J Clin Microbiol 48:4083-4088.
15. Ostrosky-Zeichner L, Alexander BD, Kett DH, Vazquez J, Pappas PG, et al. ((2005)) Multicenter clinical evaluation of the (1-&3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 41:654-659.
16. Ostrosky-Zeichner L, Pappas PG, ((2006)) Invasive candidiasis in the intensive care unit. Crit Care Med 34:857-863.
17. Ikemura K, Ikegami K, Shimazu T, Yoshioka T, Sugimoto T, ((1989)) False-positive result in Limulus test caused by Limulus amebocyte lysate-reactive material in immunoglobulin products. J Clin Microbiol 27:1965-1968.
18. Kanamori H, Kanemitsu K, Miyasaka T, Ameku K, Endo S, et al. ((2009)) Measurement of (1-3)-beta-D-glucan derived from different gauze types. Tohoku J Exp Med 217:117-121.
19. Kanda H, Kubo K, Hamasaki K, Kanda Y, Nakao A, et al. ((2001)) Influence of various hemodialysis membranes on the plasma (1-&3)-beta-D-glucan level. Kidney Int 60:319-323.
20. Kimura Y, Nakao A, Tamura H, Tanaka S, Takagi H, ((1995)) Clinical and experimental studies of the limulus test after digestive surgery. Surg Today 25:790-794.
21. Marty FM, Lowry CM, Lempitski SJ, Kubiak DW, Finkelman MA, et al. ((2006)) Reactivity of (1-&3)-beta-d-glucan assay with commonly used intravenous antimicrobials. Antimicrob Agents Chemother 50:3450-3453.
22. Mennink-Kersten MA, Warris A, Verweij PE, ((2006)) 1,3-beta-D-glucan in patients receiving intravenous amoxicillin-clavulanic acid. N Engl J Med 354:2834-2835.
23. Nagasawa K, Yano T, Kitabayashi G, Morimoto H, Yamada Y, et al. ((2003)) Experimental proof of contamination of blood components by (1-&3)-beta-D-glucan caused by filtration with cellulose filters in the manufacturing process. J Artif Organs 6:49-54.
24. Ogawa M, Hori H, Niiguchi S, Azuma E, Komada Y, ((2004)) False-positive plasma (1-&3)-beta-D-glucan test following immunoglobulin product replacement in an adult bone marrow recipient. Int J Hematol 80:97-98.
25. Usami M, Ohata A, Horiuchi T, Nagasawa K, Wakabayashi T, et al. ((2002)) Positive (1-&3)-beta-D-glucan in blood components and release of (1-&3)-beta-D-glucan from depth-type membrane filters for blood processing. Transfusion 42:1189-1195.
26. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, et al. ((2008)) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46:1813-1821.
27. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, et al. ((2009)) Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases 48:503-535.
28. Senn L, Eggimann P, Ksontini R, Pascual A, Demartines N, et al. ((2009)) Caspofungin for prevention of intra-abdominal candidiasis in high-risk surgical patients. Intensive Care Med 35:903-908.
29. van Burik JA, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, et al. ((2004)) Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39:1407-1416.
30. Rex JH, ((2006)) Antifungal prophylaxis in the intensive care unit: Who should get it? Critical Care Medicine 34: 1286-1287 1210.1097/1201.
31. Ostrosky-Zeichner L SJ, Pappas P, Shoham S, Barron M, Reboli A, et al. ((2007)) Pilot Study of Risk-Based Caspofungin Prophylaxis in the ICU: Lessons from a Multicenter, Randomized, Double Blind Trial and Insights into Diagnostic Performance of Surrogate Markers; 2007; Chicago, IL. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy.
32. Ellis M, Al-Ramadi B, Finkelman M, Hedstrom U, Kristensen J, et al. ((2008)) Assessment of the clinical utility of serial beta-D-glucan concentrations in patients with persistent neutropenic fever. J Med Microbiol 57:287-295.
33. Obayashi T, Yoshida M, Mori T, Goto H, Yasuoka A, et al. ((1995)) Plasma (1-&3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 345:17-20.
34. Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F, et al. ((2004)) Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 39:199-205.
35. Pickering JW, Sant HW, Bowles CA, Roberts WL, Woods GL, ((2005)) Evaluation of a (1-&3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 43:5957-5962.
36. Ostrosky-Zeichner L, Kullberg BJ, Bow EJ, Hadley S, León C, et al. ((2011)) Early treatment of candidemia in adults: a review. Medical Mycology 49:113-120.
37. Digby J, Kalbfleisch J, Glenn A, Larsen A, Browder W, et al. ((2003)) Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients. Clin Diagn Lab Immunol 10:882-885.
38. Mohr JF, Sims C, Paetznick V, Rodriguez J, Finkelman MA, et al. ((2011)) Prospective survey of (1-&3)-beta-D-glucan and its relationship to invasive candidiasis in the surgical intensive care unit setting. J Clin Microbiol 49:58-61.
39. Presterl E, Parschalk B, Bauer E, Lassnigg A, Hajdu S, et al. ((2009)) Invasive fungal infections and (1,3)-beta-D-glucan serum concentrations in long-term intensive care patients. Int J Infect Dis 13:707-712.
40. Takesue Y, Kakehashi M, Ohge H, Imamura Y, Murakami Y, et al. ((2004)) Combined assessment of beta-D-glucan and degree of candida colonization before starting empiric therapy for candidiasis in surgical patients. World J Surg 28:625-630.
41. Jaijakul S VJ, Swanson RN, Ostrosky-Zeichner L (1,3)-B-D-Glucan (BG) as a Prognostic Marker of Treatment Response in Invasive Candidiasis; 2011; Chicago.